Insulin-induced glucose control improves HDL cholesterol levels but not reverse cholesterol transport in type 2 diabetic patients

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 415-417

  Fadini, Gian Paolo ^a,b   Iori, Elisabetta ^a   Marescotti, Maria Cristina ^a   Vigili de Kreutzenberg, Saula ^a   Avogaro, Angelo ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Atherosclerosis; Cardiovascular risk; Cholesterol; Diabetes; HDL

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN DETEMIR; INSULIN GLARGINE; TRIACYLGLYCEROL; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADD ON THERAPY; AGED; ARTICLE; BODY WEIGHT; BRAIN ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CROSSOVER PROCEDURE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL;

AGED; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; MALE;

EID: 84921526044     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.942     Document Type: Article

References (11)

1. Seshasai S.R., Kaptoge S., Thompson A., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. NEngl J Med 2011, 364:829-841.
2. Avogaro A., de Kreutzenberg S.V., Fadini G.P. Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract 2008, S94-S101.
3. Avogaro A., Albiero M., Menegazzo L., de Kreutzenberg S., Fadini G.P. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 2011, 2(34 Suppl):S285-S290.
4. Schaper N.C., Havekes B. Diabetes: impaired damage control. Diabetologia 2012, 55:18-20.
5. Fadini G.P., de Kreutzenberg S.V., Boscaro E., et al. An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia 2013, 56:1856-1866.
6. Fadini G.P. Areappraisal of the role of circulating (progenitor) cells in the pathobiology of diabetic complications,. Diabetologia 2014, 57:4-15.
7. Besler C., Luscher T.F., Landmesser U. Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 2012, 4:251-268.
8. Farbstein D., Levy A.P. HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther 2012, 10:353-361.
9. Luscher T.F., Landmesser U., von Eckardstein A., Fogelman A.M. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 2014, 114:171-182.
10. Fadini G.P., de Kreutzenberg S.V., Mariano V., et al. Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes Obes Metab 2011, 13:718-725.
11. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. NEngl J Med 2011, 364:127-135.